Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.74 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.74 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.74 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.74 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.74 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.71 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | USP2 | O75604 | 2/20 | 0.66 |
| ▸ | F12 | P00748 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.64 |
| ▸ | CA9 | Q16790 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | NT5E | P21589 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15066602 | 0.87 | MAOA (0.77) | MAOAGRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL1367996 | 0.87 | GRIN1 (0.79) | MAOAGRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL1367953 | 0.87 | GRIN1 (0.79) | MAOAGRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL569881 | 0.85 | GPR35 (1.00) | MAOAGRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL3273927 | 0.84 | GRIN1 (0.74) | MAOAGRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL1808756 | 0.83 | MAOA (0.71) | MAOAGRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL1365809 | 0.83 | GRIN1 (0.72) | MAOAGRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL14642321 | 0.82 | MAOB (0.77) | MAOAMAOBALDH1A1F12KDM4E | |
| SCHEMBL3065914 | 0.81 | TSHR (0.71) | MAOAGRIN1GRIN2AGRIN2BGRIN2C | |
| SCHEMBL17037285 | 0.81 | MAOB (1.00) | MAOAGPR35MAOBALDH1A1F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108690042-B | Simultaneous detection of ONOO-And H2Fluorescent probe of S and synthetic method and application thereof | 山东师范大学 | 2020-03-27 | — | — | CN | claimed |
| CN-108690042-B | Simultaneous detection of ONOO-And H2Fluorescent probe of S and synthetic method and application thereof | 山东师范大学 | 2020-03-27 | — | — | CN | disclosed |
| US-9518038-B2 | Condensation product of theanine derivative and carboxylic acid coumarin derivative, its intermediate, preparation method and use thereof | SHANDONG YINGDONG YINGHAO BIOTECHNOLOGY, INC. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-20150239861-A1 | CONDENSATION PRODUCT OF THEANINE DERIVATIVE AND CARBOXYLIC ACID COUMARIN DERIVATIVE, ITS INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | ZHANG, GUOYING (CN) | 2015-08-27 | — | — | US | disclosed |
| EP-2825261-A1 | POLYPEPTIDES AND THEIR USE | Novabiotics Limited (GB) | 2015-01-21 | — | — | EP | disclosed |
| US-20140155321-A1 | Polypeptides and Their Use | NOVABIOTICS LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| WO-2013136040-A1 | POLYPEPTIDES AND THEIR USE | NOVABIOTICS LIMITED (GB) | 2013-09-19 | — | — | WO | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| CN-101014580-B | Morpholine compound | MITSUBISHI PHARMA CORP | 2011-05-04 | — | — | CN | disclosed |
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1519941-A2 | A METHOD OF CLEAVING LABILE FUNCTIONAL GROUPS FROM CHEMICAL COMPOUNDS | Chemogenix GmbH (DE) | 2005-04-06 | — | — | EP | disclosed |
| EP-1480927-A2 | A METHOD FOR CLEAVAGE OF LABILE FUNCTIONAL GROUPS FROM CHEMICAL COMPOUNDS | Universität Konstanz (DE) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004089529-A1 | METHOD FOR THE INTRAMOLECULAR ENERGY TRANSFER FOR THE CLEAVAGE OF LABILE FUNCTIONAL GROUP FROM BIOMOLECULES AND THE PROTECTED BIOMOLECULES | Universität Konstanz (DE) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004016349-A2 | METHOD AND DEVICE FOR THE INTERMOLECULAR TRANSPORT OF BOND CLEAVAGE ACTIVATION ENERGY THROUGH SPACE | CHEMOGENIX GMBH (DE) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004001033-A2 | A METHOD OF CLEAVING LABILE FUNCTIONAL GROUPS FROM CHEMICAL COMPOUNDS | CHEMOGENIX GMBH (DE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003074542-A2 | A METHOD FOR CLEAVAGE OF LABILE FUNCTIONAL GROUPS FROM CHEMICAL COMPOUNDS | Universität Konstanz (DE) | 2003-09-12 | — | — | WO | disclosed |
| US-20030035917-A1 | Image making medium | HYMAN SYDNEY (US) | 2003-02-20 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148599-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, VEGFA, FLT4 | MAOA 1059/4885GRIN1 4816/4885GRIN2A 4803/4885 |
| US-20150239861-A1 | CONDENSATION PRODUCT OF THEANINE DERIVATIVE AND CARBOXYLIC ACID COUMARIN DERIVATIVE, ITS INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | OGDH, C9, IRAK3 | MAOA 3987/4885GRIN1 2917/4885GRIN2A 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.